Sexual dysfunction in women is common and often goes unreported and untreated. Its management is part of patient-centered primary care. Primary care providers are uniquely positioned to identify and assess sexual health concerns of their patients, provide reassurance regarding normal sexual function, and treat sexual dysfunction or refer as appropriate.
M
any women experience some form of sexual dysfunction, be it lack of desire, lack of arousal, failure to achieve orgasm, or pain during sexual activity.
Sexual health may be diffi cult to discuss, for both the patient and the provider. Here, we describe how primary care physicians can approach this topic, assess potential problems, and begin treatment.
■ A COMMON PROBLEM
The age-adjusted prevalence of sexual dysfunction in US women was reported at 44% in the Prevalence of Female Sexual Problems Associated With Distress and Determinants of Treatment Seeking (PRESIDE) study, 1 but the prevalence of distress associated with sexual dysfunction was 12%. The most common type of sexual dysfunction reported by women was low sexual desire, a fi nding consistent with that of another large population-based study. 2 While the prevalence of any type of sexual dysfunction was highest in women over age 65, 1 the prevalence of distress was lowest in this age group and highest in midlife between the ages of 45 and 65. The diagnostic criteria require both a problem and distress over the problem.
Sexual dysfunction negatively affects quality of life and emotional health, regardless of age. 3 
■ LIFESTYLE AND SEXUAL FUNCTION
Various lifestyle factors have been linked to either more or less sexual activity. For example, a Mediterranean diet was associated with increased sexual activity, as were social activity, social support, psychological well-being, selfreported good quality of life, moderate alcohol Primary care providers can assess the problem, provide education on sexual health and normal sexual functioning, and manage biological factors affecting sexual function, including genitourinary syndrome of menopause in postmenopausal women and antidepressant-induced sexual dysfunction.
Treatment may require a multidisciplinary team, including a psychologist or sex therapist to manage the psychological, sociocultural, and relational factors affecting a woman's sexual health, and a physical therapist to manage pelvic fl oor disorders.
intimacy is an important part of the cycle, and emotional closeness and bonding with the partner may provide motivation for a woman to enter into the cycle again in the future.
In a Danish survey, 12 more people of both sexes said the 2 linear models described their experiences better than the circular model, but more women than men endorsed the circular model, and more men than women endorsed a linear model.
In evaluating women who complain of low sexual desire, clinicians should be aware that women, particularly those who are postmenopausal, may not enter the cycle with spontaneous sexual desire, but instead may experience arousal in response to a sexual stimulus followed by desire-ie, responsive rather than spontaneous sexual desire. Sexual arousal may precede desire, especially for women in long-term relationships, and emotional intimacy is a key driver for sexual engagement in women.
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■ CATEGORIES OF SEXUAL DYSFUNCTION IN WOMEN
The World Health Organization defi nes sexual health as "a state of physical, emotional, mental, and social well-being in relation to sexuality" and "not merely the absence of disease, dysfunction, or infi rmity." 13 The 
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tions of the DSM. Proponents of merging the 2 categories in DSM-5 cited several reasons, including diffi culty in clearly distinguishing desire from other motivations for sexual activity, the relatively low reporting of fantasy in women, the complexity of distinguishing spontaneous from responsive desire, and the common co-occurrence of decreased desire and arousal diffi culties. 15 Other experts, however, have recommended keeping the old, separate categories of hypoactive sexual desire disorder and arousal disorder. 16 The recommendation to preserve the diagnostic category of hypoactive sexual desire disorder is based on robust observational and registry data, as well as the results of randomized controlled trials that used the old criteria for hypoactive sexual desire disorder to assess responses to pharmacologic treatment of this condition. [17] [18] [19] In addition, this classifi cation as a separate and distinct diagnosis is consistent with the nomenclature used in the International Statistical Classifi cation of Diseases and Related Health Problems, 10th Revision and was endorsed by the International Consultation on Sexual Medicine in 2015. 16 
■ HOW TO ASK ABOUT SEXUAL HEALTH
Assessment of sexual health concerns should be a part of a routine health examination, particularly after childbirth and other major medical, surgical, psychological, and life events. Women are unlikely to bring up sexual health concerns with their healthcare providers, but instead hope that their providers will bring up the topic. 20 Barriers to the discussion include lack of provider education and training, patient and provider discomfort, perceived lack of time during an offi ce visit, and lack of approved treatments. 21, 22 Additionally, older women are less likely than men to discuss sexual health with their providers. 23 Other potential barriers to communication include negative societal attitudes about sexuality in women and in older individuals. 24, 25 To overcome these barriers:
Legitimize sexual health as an important health concern and normalize its discussion as part of a routine clinical health assessment. Prefacing a query about sexual health with a normalizing and universalizing statement can help: eg, "Many women going through menopause have concerns about their sexual health. Do you have any sexual problems or concerns?" Table 1 contains examples of questions to use for initial screening for sexual dysfunction. 22, 26 Flynn et al 27 proposed a validated singlequestion checklist to screen for sexual dysfunction that is an effi cient way to identify specifi c sexual concerns, guide selection of interventions, and facilitate patient-provider communication ( Table 2) . Don't judge and don't make assumptions about sexuality and sexual practices.
Assure confi dentiality. Use simple, direct language that is appro- Take a thorough history (sexual and reproductive, medical-surgical, and psychosocial).
■ PHYSICAL EXAMINATION
Perform a focused physical examination to evaluate for potential causes of pain (eg, infectious causes, vulvar dermatoses, pelvic fl oor muscle dysfunction). The examination is also an opportunity to teach the patient about anatomy and normal sexual function.
No standard laboratory tests or imaging studies are required for the assessment of sexual dysfunction. 28 
■ IT'S NOT JUST PHYSICAL
Evaluation and treatment of female sexual dysfunction is guided by the biopsychosocial model, with potential infl uences from the biological, psychological, sociocultural, and interpersonal realms (Table 3) . 29, 30 Biological factors include pelvic surgery, cancer and its treatment, neurologic diseases, and vascular diseases. Medications, including antidepressants, narcotics, anticholinergics, antihistamines, antihypertensives, oral contraceptives, and antiestrogens may also adversely affect sexual response.
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Psychological factors include a history of sexual abuse or trauma, body image concerns, distraction, stress, anxiety, depression, and personality disorders.
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Sociocultural factors include lack of sex education, unrealistic expectations, cultural norms, and religious infl uences.
Relationship factors include confl ict with one's partner, lack of emotional intimacy, absence of a partner, and partner sexual dysfunction. While there appears to be a close link between sexual satisfaction and a woman's relationship with her partner in correlational studies and in clinical experience, there has been little research about relationship factors and their contribution to desire and arousal concerns. 31 Sexual dysfunction in one's partner (eg, erectile dysfunction) has been shown to negatively affect the female partner's sexual desire. 32 
■ GENERAL APPROACH TO TREATMENT
In treating sexual health problems in women, we address contributing factors identifi ed during the initial assessment.
A multidisciplinary approach
As sexual dysfunction in women is often multifactorial, management of the problem is well suited to a multidisciplinary approach. The team of providers may include: • A medical provider (primary care provider, gynecologist, or sexual health specialist) to coordinate care and manage biological factors contributing to sexual dysfunction • A physical therapist with expertise in treating pelvic fl oor disorders • A psychologist to address psychological, relational, and sociocultural contributors to sexual dysfunction • A sex therapist (womenshealthapta.org, aasect.org) to facilitate treatment of tight, tender pelvic fl oor muscles through education and guidance about kinesthetic awareness, muscle relaxation, and dilator therapy. 33 Even in the initial visit, the primary care provider can educate, reassure regarding normal sexual function, and treat conditions such as genitourinary syndrome of menopause and antidepressant-associated sexual dysfunction.
Women are unlikely to bring up sexual health concerns with their healthcare provider, but instead hope that their provider will bring up the topic Reproduced with permission of Springer.
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The PLISSIT model (Permission, Limited Information, Specifi c Suggestions, and Intensive Therapy) is a useful tool for initiating counseling about sexual health ( Table 4) . 34 
■ AGING VS MENOPAUSE
Aging can affect sexual function in both men and women. About 40% of women experience changes in sexual function around the menopausal transition, with common complaints being loss of sexual responsiveness and desire, sexual pain, decreased sexual activity, and partner sexual dysfunction. 35 However, studies seem to show that while menopause results in hormonal changes that affect sexual function, other factors may have a greater impact.
The Study of Women's Health Across the Nation 36 found vaginal and pelvic pain and decreased sexual desire were associated with the menopausal transition, but other sexual health outcomes (frequency of sexual activities, arousal, importance of sex, emotional satisfaction, or physical pleasure) were not. Physical and psychological health, marital status, and a change in relationship were all associated with differences in sexual health.
The Massachusetts Women's Health Study II 37 found a greater association between physical and mental health, relationship status, and smoking and women's sexual functioning than menopausal status.
The Penn Ovarian Aging Study 38 found that sexual function declined across the menopausal transition. Risk factors for sexual dysfunction included postmenopausal status, anxiety, and absence of a sexual partner.
The Melbourne Women's Midlife Health Project 39 also found that sexual function declined across the menopausal transition. Sexual dysfunction with distress was associated with relationship factors and depression.
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Genitourinary syndrome of menopause and its treatment As the ovaries shut down during menopause, estradiol levels decrease. Nearly 50% of women experience symptoms related to genitourinary syndrome of menopause (formerly called atrophic vaginitis or vulvovaginal atrophy). 40, 41 These symptoms include vaginal dryness and discomfort or pain with sexual activity, but menopausal hormone loss can also result in reduced genital blood fl ow, decreased sensory perception, and decreased sexual responsiveness. 22 Estrogen is the most effective treatment for genitourinary syndrome of menopause, with low-dose vaginal preparations preferred over systemic ones for isolated vulvar and vaginal symptoms. 40 While estrogen is effective for vaginal dryness and sexual pain associated with estrogen loss, replacing estrogen systemically has not been associated with improvements in sexual desire. 42 
■ DEPRESSION AND ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION
Depression increases the risk of sexual dysfunction, and vice versa. A meta-analysis that included 12 studies involving almost 15,000 patients confi rmed that depression increased the risk of sexual dysfunction, and sexual dysfunction increased the risk of depression. 43 This interaction may be related to the overlap in affected neurotransmitters and neuroendocrine systems. 44 In the Sequenced Treatment Alternatives to Relieve Depression trial, Ishak et al 45 found that patients treated with a selective serotonin reuptake inhibitor (SSRI) who experienced remission of depression had a lower prevalence of impaired sexual satisfaction and much greater improvements in sexual satisfaction than did those who remained depressed. 
Sexual dysfunction in women is often multifactorial
Replacing estrogen systemically has not been associated with improvements in sexual desire
The severity of depressive symptoms predicted impairment in sexual satisfaction, which in turn predicted poorer quality of life. The authors suggested that physicians encourage patients to remain on SSRI treatment, given that improvement in depressive symptoms is likely to improve sexual satisfaction.
Antidepressant-induced sexual dysfunction
As many as 70% of patients taking an SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) experience antidepressant-induced sexual dysfunction, though this is diffi cult to estimate across studies of different medications due to differences in methods and because many patients only report it when directly asked about it. 46 Treatment of antidepressant-induced sexual dysfunction includes not only optimal management of depression but reassessment of the antidepressant treatment. If using only nondrug treatments for the mood disorder is not feasible, switching to (or ideally, starting with) an antidepressant with fewer sexual side effects such as mirtazapine, vilazodone, or bupropion is an option. 46 A drug holiday (suspending antidepressant treatment for 1 or 2 days) has been suggested as a means of treating antidepressant-induced sexual dysfunction, but this may result in poorer control of depressive symptoms and discontinuation symptoms, and it encourages medication noncompliance. 46, 47 Treatment with a phosphodiesterase type 5 inhibitor (eg, sildenafi l) has been studied in women with antidepressant-induced sexual dysfunction, with modest results. 48 A Cochrane review reported that treatment with bupropion shows promise at higher doses (300 mg daily). 49 Exercise for 20 minutes 3 times weekly is associated with improvement in antidepressant-induced sexual dysfunction when the exercise is performed immediately before sexual activity. 50 
■ LOW SEXUAL DESIRE
Hypoactive sexual desire disorder is defi ned as persistent or recurrent defi ciency or absence of sexual fantasies and desire for sexual activity associated with marked distress and not due exclusively to a medication, substance abuse, or a medical condition.
Low or decreased sexual desire is the most commonly reported sexual health concern in women of all ages, with an unadjusted prevalence of 39.7%. When the criterion of personal distress is included, the prevalence is 8.9% in women ages 18 to 44, 12.3% in women ages 45 to 64, and 7.4% in women ages 65 and older. 1 Multiple biological, psychological, and social factors may contribute to the problem. Identifying the ones that are present can help in planning treatment. A multifaceted approach may be appropriate.
TABLE 4
Talking about sex: The PLISSIT model Permission: Give patient permission to speak about sexual health and validate her sexual choices and preferences (eg, legitimize her decision to participate in sexual activity on her own terms).
Limited information: Provide basic sex education regarding anatomy, physiology, and normal sexual response; offer educational resources (eg, literature, videos, and erotica).
Specifi c suggestions:
Provide concrete suggestions to improve/enhance sexual function (eg, lubricant, vibrator or dilator use, self-stimulation, technical advice about sexual positioning, ways to increase emotional intimacy and communication). 
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Mindfulness and cognitive behavioral therapy for low sexual desire
Mindfulness-based cognitive therapy is designed to improve awareness, focusing on and accepting the present moment, and directing attention away from and lessening self-criticism and evaluation of one's sexual responsiveness. Mindfulness-based therapy has been associated with improvements in sexual desire and associated distress. 51 Similarly, the effectiveness of cognitive behavioral therapy for treating hypoactive sexual desire disorder is supported by 3 controlled trials, although concerns exist about the adequacy of these trials, and further study is needed.
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Androgen therapy in women
In randomized controlled trials in women with low sexual desire who were either naturally or surgically menopausal, sexual function improved with testosterone therapy that resulted in mostly supraphysiologic total testosterone levels (which may not refl ect free testosterone levels) with or without concurrent estrogen treatment. [53] [54] [55] [56] [57] Testosterone is not approved by the US Food and Drug Administration (FDA) for use in women, primarily because of the lack of long-term safety and effi cacy data (ie, beyond 24 months). However, studies have shown no evidence of increased risk of endometrial cancer or cardiovascular disease with testosterone dosed to achieve physiologic premenopausal levels. 58 Data on breast cancer risk are less clear, but observational studies over the last decade do not support an association with testosterone use in women. 58 There is no clearly defi ned androgen defi ciency syndrome in women, and androgen levels do not reliably correlate with symptoms. 59 The Endocrine Society 59 guidelines endorse the use of testosterone in postmenopausal women with hypoactive sexual desire disorder. They say to aim for the midnormal premenopausal range and suggest discontinuing the drug if there is no response in 6 months. They recommend checking testosterone levels at baseline, after 3 to 6 weeks of therapy, and every 6 months to monitor for excessive use, to avoid supraphysiologic dosing and to evaluate for signs of androgen excess (eg, acne, hair growth). The use of products formulated for men or those formulated by pharmacies is discouraged; however, no FDA-approved products are currently available for use in women in the United States.
Flibanserin
A postsynaptic serotonin 5-HT1A receptor agonist and 5-HT2A receptor agonist, fl ibanserin was approved by the FDA in 2015 for treatment of hypoactive sexual desire disorder in premenopausal women. Its mechanism of action is likely through an effect on neurotransmitters that suppresses serotonin (which has sexually inhibitory effects) and promotes dopamine and norepinephrine (which have excitatory effects). 60 The effi cacy of fl ibanserin has been demonstrated in 3 randomized controlled trials, with signifi cant increases in the number of sexually satisfying events and in sexual desire scores and a decrease in distress associated with low sexual desire. 17 -19 While the increase in sexually satisfying events was modest (about 1 extra event per month), some have suggested that the frequency of sexual activity may not be the best measure of sexual function in women. 61 Further, responders to this drug showed a return to near-normal premenopausal frequencies of sexual activity in a separate analysis. 61 The drug is generally well tolerated, with common adverse effects being somnolence, dizziness, and fatigue. 18, 19 Flibanserin has been associated with orthostatic hypotension with alcohol use and carries a boxed warning highlighting this potential interaction. 62 Use of this drug is contraindicated in women who drink alcohol or take medications that are moderate or strong inhibitors of CYP-3A4 (eg, some antiretroviral drugs, antihypertensive drugs, antibiotics, and fl uconazole, which can increase systemic exposure to fl ibanserin and potential side effects), and in those with liver impairment.
■ SEXUAL AROUSAL DISORDERS
Female sexual arousal disorder is the persistent or recurrent inability to attain or maintain an adequate lubrication-swelling response of sexual excitement. Sexual arousal results from a complex interaction between genital response, central nervous system activity, and Depression increases the risk of sexual dysfunction, and vice versa information processing of the sexual stimulus. Diffi culty with sexual arousal can result from neurovascular or neuroendocrine dysfunction or impaired central nervous system processing.
Women may experience a mismatch between subjective and objective genital arousal. A subjective report of decreased genital arousal may not be confi rmed with measurement of vaginal pulse amplitude by photoplethysmography. 63 Even in postmenopausal women, in the absence of signifi cant neurovascular or neuroendocrine dysfunction, it is likely that either contextual or relational variables resulting in inadequate sexual stimulation or cognitive inhibition are more important factors contributing to diffi culty with sexual arousal. 63 Although there are no standard recommendations for evaluation of arousal disorders and advanced testing is often unnecessary, nerve function can be assessed with genital sensory testing utilizing thermal and vibratory threshholds 64 ; vaginal blood fl ow can be assessed with vaginal photoplethysmography 63 ; and imaging of the spine and pelvis can help to rule out neurovascular pathology.
Treatment of arousal disorders
As with other forms of female sexual dysfunction, treatment of arousal disorders includes addressing contributing factors.
Although there are few data from randomized controlled trials, psychological treatments such as sensate focus exercises and masturbation training have been suggested, centered on women becoming more self-focused and assertive. 31 Sensate focus exercises are a series of graded, nondemand, sensual touching exercises aimed at reducing anxiety and avoidance of sexual activity, and improving sexual communication and intimacy by the gradual reintroduction of sexual activity. 65 More recently, mindfulness-based cognitive therapy has been associated with improvements in sexual arousal as well as other parameters of sexual function. 51 Currently, no pharmacologic treatments are recommended for arousal disorders because of a lack of evidence of effi cacy and because of adverse effects. 31 
■ ORGASMIC DISORDER
Female orgasmic disorder is the marked delay, marked infrequency, or absence of orgasm, or markedly reduced intensity of orgasm.
Important considerations in evaluating orgasm disorders include psychosocial factors (eg, lack of sex education, negative feelings about sex, religiosity), psychological factors (eg, anxiety, depression, body image concerns), relational factors (eg, communication issues, lack of emotional intimacy, partner sexual dysfunction), adverse childhood or adult experiences (eg, physical, sexual, or emotional or verbal abuse), medical history (pelvic surgery, neurologic, or vascular disease) and medications (eg, SSRIs, SNRIs, and antipsychotic medications).
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Treatment of orgasmic disorder
Involving the partner in treatment is important, particularly if the diffi culty with orgasm is acquired and only occurs with sex with a partner. Using the PLISSIT model to provide targeted, offi ce-based interventions can be helpful.
Behavioral therapies such as directed masturbation, sensate focus exercises, or a combination of these have been shown to be effective, as has coital alignment during intercourse (positioning of male partner with his pelvis above the pubic bone of his partner to maximize clitoral stimulation with penile penetration). 66 Hormonal therapy may be useful in postmenopausal women. However, there are no data on it for women whose primary complaint is female orgasmic disorder, and further study is needed. 66 
■ SEXUAL PAIN DISORDERS
The DSM-5 describes genitopelvic pain/penetration disorder as fear or anxiety, marked tightening or tensing of abdominal and pelvic muscles, or actual pain with vaginal penetration that is recurrent or persistent for a minimum of 6 months.
14 Pain may occur with initial penetration, with deeper thrusting, or both.
Although the DSM-5 defi nition focuses on pain with penetration, it is important to recognize and ask about noncoital sexual pain. Women may also present with persistent vulvar pain or pain at the vulvar vestibule with provocation, (eg, sexual activity, tampon insertion, sitting), also known as provoked vestibulodynia. Low or decreased sexual desire is the most commonly reported sexual health concern in women of all ages FAUBION AND PARISH Assessment of vaginal and vulvar pain includes a directed history and physical examination aimed at identifying potential etiologies or contributing factors, including infectious, infl ammatory, neoplastic, neurologic, traumatic, iatrogenic, or factors related to hormonal defi ciency.
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Treatment of sexual pain
Removal of offending agents is a fi rst step. This includes a thorough review of vulvar and vaginal hygiene practices and emphasis on avoiding the use of any product containing potential irritants (eg, soaps or detergents containing perfumes or dyes) and using lubricants and moisturizers without gimmicks (no warming or tingling agents or fl avors). Oral contraceptives have been associated with vestibulodynia, and women in whom the sexual pain started when they started an oral contraceptive may benefi t from switching to an alternate form of contraception. 68 Dysfunction of pelvic fl oor muscles may result in sexual pain and may be a primary problem or a secondary complication related to other issues such as symptomatic genitourinary syndrome of menopause. The symptoms of nonrelaxing pelvic fl oor dysfunction (also known as hypertonic pelvic fl oor dysfunction or pelvic fl oor tension myalgia) include pain in the pelvis with sexual activity that may linger for hours or even days, and may also include bowel and bladder dysfunction and low back pain or hip pain radiating to the thighs or groin. 33 Physical therapy under the care of a physical therapist with expertise in the management of pelvic fl oor disorders is the cornerstone of treatment for this condition. 33 Treatment of the genital and urinary symptoms related to loss of estrogen after menopause (genitourinary syndrome of menopause) includes the use of vaginal lubricants with sexual activity and vaginal moisturizers on a regular basis (2 to 5 times per week). 40 Lowdose vaginal estrogen creams, rings, or tablets and the oral selective estrogen receptor antagonist ospemifene are recommended for moderate to severe symptoms of genitourinary syndrome of menopause. 40 Intravaginal dehydroepiandrosterone was recently approved by the FDA for treatment of dyspareunia associated with menopause. 69 Topical lidocaine applied to the introitus before sexual activity has been found to be effective for reducing sexual pain in women with breast cancer, and when used in combination with vaginal lubricants and moisturizers is a practical option for women, particularly those unable to use estrogenbased therapies. 70 
■ ■ REFERENCES
